Template:Second-generation BTKi table: Difference between revisions
From Embryology
(Created page with "{| |+ Novel BTK inhibitors in development for treatment of CLL |- ! BTK inhibitor ! BTK binding mechanism ! Selectivity for BTK ! Relevant non-BTK targets ! Phase of clinical...") |
mNo edit summary |
||
| Line 1: | Line 1: | ||
{| | {| | ||
|+ Novel BTK | |+ '''Novel BTK Inhibitors for CCL Treatment''' | ||
|- | |- | ||
! BTK inhibitor | ! BTK inhibitor | ||
| Line 8: | Line 8: | ||
! Phase of clinical development | ! Phase of clinical development | ||
|- | |- | ||
Acalabrutinib | | Acalabrutinib | ||
| Covalent, irreversible | |||
| High | |||
| N/A | |||
| II/III | |||
Covalent, irreversible Covalent, irreversible | |- | ||
| Zanubrutinib | |||
| Covalent, irreversible | |||
| Moderate | |||
| N/A | |||
N/A | | II/III | ||
|- | |||
| Tirabrutinib | |||
| Covalent, irreversible | |||
| High | |||
LYN, MEK1 | | N/A | ||
| I/II | |||
|- | |||
| Vecabrutinib | |||
| Non-covalent, reversible | |||
| Moderate | |||
| interleukin-2-inducible (ITK) | |||
| I/II | |||
|- | |||
| LOXO-305 | |||
| Non-covalent, reversible | |||
| High | |||
| N/A | |||
| I | |||
|- | |||
| ARQ-531 | |||
| Non-covalent, reversible | |||
| Low | |||
| Lck/Yes novel tyrosine kinase (LYN), mitogen-activated protein kinase kinase 1 (MEK1) | |||
| I | |||
|- | |- | ||
| colspan=5|Table data {{#pmid:31028669|PMID31028669}} | | colspan=5|Table data {{#pmid:31028669|PMID31028669}} | ||
|} | |} | ||
Revision as of 15:00, 30 April 2019
| BTK inhibitor | BTK binding mechanism | Selectivity for BTK | Relevant non-BTK targets | Phase of clinical development |
|---|---|---|---|---|
| Acalabrutinib | Covalent, irreversible | High | N/A | II/III |
| Zanubrutinib | Covalent, irreversible | Moderate | N/A | II/III |
| Tirabrutinib | Covalent, irreversible | High | N/A | I/II |
| Vecabrutinib | Non-covalent, reversible | Moderate | interleukin-2-inducible (ITK) | I/II |
| LOXO-305 | Non-covalent, reversible | High | N/A | I |
| ARQ-531 | Non-covalent, reversible | Low | Lck/Yes novel tyrosine kinase (LYN), mitogen-activated protein kinase kinase 1 (MEK1) | I |
| Table data [1] | ||||